Tejas Patil, MD
Assistant Professor, Medicine-Medical Oncology

Assistant Professor
Featured Provider Photo

Gender: Male
Languages:
Department, Section/Division: Medicine-Medical Oncology

Practice Locations

UCHealth Lung Cancer Clinic - Anschutz Medical Campus
1665 Aurora Ct
Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300
More providers at this location

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
More providers at this location

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine - Hematology and Oncology, Board Certification (2020)
  • Internal Medicine, Board Certification (2016)
Conditions & Treatments
  • Cancers
  • Cancer Medicine
  • Lung Cancer
Clinical Interest for Patients
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.

Care Philosophy
I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.

Personal Interests
I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.

Public Speaking
Yes
I have given multiple lectures on advances in precision oncology, targeted therapies and acquired resistance.

Information for Referring Providers

Clinical Interests for Referring Providers
My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.

Research Interest for Referring Providers
My translational research interests in lung cancer focus on three main themes: (1) leveraging molecular testing to identify prognostic and potentially predictive biomarkers to guide sequencing of anti-cancer therapies, (2) understanding the mechanisms of acquired resistance to targeted therapies, and (3) using evolutionary principles to develop rational anticancer therapy combinations to eradicate cancer persistence.